Safety and tolerablilty of HPV mRNA vaccine in HPV-driven squamous cell carcinoma.
Phase of Trial: Phase I/II
Latest Information Update: 06 Feb 2018
At a glance
- Drugs RBLO15.1(LIP)/RBLO16.1(LIP) (Primary)
- Indications Cervical cancer; Head and neck cancer; Penile cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms HARE-40
- 22 Jan 2018 Status changed from active, no longer recruiting to recruiting.
- 27 Sep 2017 New source identified and integrated European Clinical Trials Database (EudraCT2014-002061-30).
- 26 Sep 2017 New trial record